Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
Approved
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] is one of 8 therapeutic programs targeting Urgency Urinary Incontinence. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in Urgency Urinary Incontinence
#DrugCompanyPhaseTrials
1Vesicare
AstellasApproved
Myrbetriq
AstellasApproved
Oxytrol
WWim Janssens
Approved
Sanctura Xr
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Onabotulinumtoxina 100 UNT
SStanford University
Approved
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
WWomen and Infants Hospital of Rhode Island
Approved
Beta3-Agonists, Adrenergic
MMansoura University
Approved
Botox
RRevance Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urgency Urinary Incontinence1 trial
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Active, not recruiting·WWomen and Infants Hospital of Rhode Island·Approved·NCT05806164·432 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]